Molnupiravir // MERCK . JAPÓN ha Iniciado Negociaciones con la Compañía Farmacéutica Estadounidense Merck & Co. Para Obtener la Aprobación Especial y la Adquisición este Año de su Medicamento Antiviral Oral Para Pacientes con COVID19 .

Merck Has Conducted Interim Clínical Trials of Its Oral Medicine, Molnupiravir, and Will Soon Seek Approval For Its Emergency Use in The United States .

Global Demand For The Medicine is Expected to Soar, so the Japanese Government plans to secure an adequate supply early through talks with the Drugmaker.

Molnupiravir is designed for COVID-19 patients with mild symptoms to prevent their conditions from worsening.

Patients need to take molnupiravir every 12 hours over five days for 10 times in total, according to the company.

The only drugs approved in Japan for patients with mild symptoms are sotrovimab and antibody cocktail Ronapreve, which are both administered through intravenous drips.

Oral drugs are expected to be in high demand because they are relatively easy to take. ...